CJC-1295 with DACWhat the studies show

The 2005 paper in Endocrinology describes the search. ConjuChem made a series of GRF 1-29 analogues with the reactive tail, let them bond to albumin, and tested whether the albumin-bound peptide still reached and activated the GHRH receptor on rat pituitary cells. It did, and the analogue with the four stabilising substitutions, numbered CJC-1295, gave the longest-lasting rise in growth hormone and IGF-1 in rats ¹.

The main human data come from a 2006 paper in the Journal of Clinical Endocrinology & Metabolism reporting two placebo-controlled studies in healthy adults, one with single injections and one with repeated ones ². After a single dose, mean growth hormone concentrations rose 2- to 10-fold for six days or more, and IGF-1 rose 1.5- to 3-fold for nine to eleven days ². The measured half-life was 5.8 to 8.1 days, which is what albumin binding predicts. With repeated dosing, IGF-1 stayed above baseline for up to 28 days after the last injection ². Side effects reported in the paper were mostly injection-site reactions, headache, flushing and diarrhoea, with no serious events ².

A second 2006 study, from Frohman's laboratory, asked a sharper question: if the pituitary is stimulated continuously for days, does it still release growth hormone in pulses, or does it flatten into a steady trickle? Healthy men were given a single injection and sampled around the clock. The pulses persisted, with the same number of them, on top of a raised baseline; the extra growth hormone showed up mainly as a higher trough and bigger pulses rather than a loss of rhythm ³. That matters because the pulsatile pattern is what the body's tissues are built to read, and because it suggests the downstream brake, somatostatin, was still working.

ConjuChem's authors were on the 2006 trial, and the company took the peptide into phase 2 for HIV-associated lipodystrophy, the same indication tesamorelin later won approval for ². It did not finish the road. CJC-1295 is not an approved drug in any country, and no phase 3 results were ever published. Whatever the reasons, the published record stops at small studies in healthy volunteers.

The human studies measured hormones in healthy adults over weeks. There is no published trial of CJC-1295 with DAC on body composition, strength, sleep or ageing, nothing beyond a few months of exposure, and no safety data in the general population. A rise in IGF-1 that lasts a month is a pharmacological fact, not a benefit, and nothing in the published work says what a sustained rise does over years. Nor has anyone published what happens to the pituitary's own brake, somatostatin, or to IGF-1 after months of continuous stimulation, which is the question the one-week studies raise and cannot answer.